Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-Cigarette, or Vaping, Product Use-Associated Lung Injury – United States, November 2019

Details

• Personal Author:
  Baldwin GT ; Briss P ; Chatham-Stephens K ; Delaney, Lisa J. ; Evans ME ; Hocevar Adkins S ; Jatlaoui TC ; Jones CM ; Kabbani S ; Kiernan EA ; King BA ; Koppaka R ; Koumans EH ; Layer M ; Legha JK ; Montandon M ; O'Hegarty M ; O'Sullivan MC ; Reagan-Steiner S ; Ritchey MD ; Rose DA ; Shealy K ; Siegel DA ; Weissman, David N. ; Wiltz JL
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) Lung Injury Response Clinical Working Group
• Description:
  What is already known about this topic? A total of 2,172 U.S. e-cigarette, or vaping, product use-associated lung injury (EVALI) cases have been reported to CDC. Vitamin E acetate and tetrahydrocannabinol appear to be associated with the outbreak; however, no single causative agent has been identified. What is added by this report? As rates of influenza increase, providers evaluating patients with respiratory illnesses should ask them about e-cigarette, or vaping, product use; evaluate whether patients require hospital admission; and consider empiric use of antimicrobials, including antivirals, as well as possible corticosteroids. What are the implications for public health practice? EVALI is a diagnosis of exclusion; rapid recognition of EVALI patients by health care providers is critical to reduce severe outcomes. [Description provided by NIOSH]
• Subjects:
  Cannabis Communicable Diseases Diagnosis Electrical Equipment And Supplies Hazardous Substances Health Personnel Influenza, Human Lung Lung Diseases Nicotine Occupational Health Public Health Radiography Respiratory System Respiratory Tract Diseases Safety Smokers Solvents Tobacco Products

  More +
• Keywords:
  Antimicrobials Antiviral Chemical Hazards Chest X-rays Cigarette Smoking Clinical Diagnosis Corticosteroids Diagnostic Techniques Electronic Devices Guidelines Health Care Personnel Health Effects Health Protection Humans Influenza Lung Disease Lung Disorders Medical Personnel Medical Screening Medical Treatment Public Health Pulmonary Disorders Pulmonary Effects Pulmonary System Disorders Safety Education Surveillance Tobacco Vapors

  More +
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Publisher:
  Centers for Disease Control and Prevention (CDC) (U.S.)
• Document Type:
  Tables
• Genre:
  Journal Article
• Place as Subject:
  California ; Georgia ; Minnesota ; Ohio ; OSHA Region 10 ; OSHA Region 3 ; OSHA Region 4 ; OSHA Region 5 ; OSHA Region 6 ; OSHA Region 8 ; OSHA Region 9 ; Texas ; Utah ; Washington ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  RHD - Respiratory Health Division ; OD - Office of the Director
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  68
• Issue:
  46
• NIOSHTIC Number:
  nn:20057840
• Citation:
  MMWR 2019 Nov; 68(46):1081-1086
• Email:
  eocevent32@cdc.gov
• CAS Registry Number:
  (-)-Nicotine (CAS RN 54-11-5) ; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, 6-acetate (CAS RN 7695-91-2) ; Tetrahydrocannabinol (CAS RN 1972-08-3) ; Tobacco oil (CAS RN 8037-19-2)
• Federal Fiscal Year:
  2020
• Peer Reviewed:
  False
• Collection(s):
  National Institute for Occupational Safety and Health Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:4215e33b22a72a8f1df74b1f0aeefb881517d382717ee08343b7dbce98cfff997af113193ed648e8a21247cfab3ebea91daa42d758bd7611f8f2c98667355ce4
• Download URL:
  https://stacks.cdc.gov/view/cdc/183321/cdc_183321_DS1.pdf
• File Type:
  [PDF - 155.65 KB ]